Tildrakizumab |
Katalog-Nr.GC72345 |
Tildrakizumab (SCH 900222) ist ein humanisierter anti-IL-23 (p19 Untereinheit) monoklonaler Antikörper.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1326244-10-3
Sample solution is provided at 25 µL, 10mM.
Tildrakizumab inhibits IL-23-induced STAT3 signaling in HeLa cells expressed the human IL-23Rα and IL-12Rβ1 receptors, with an IC50 of 23 pM[2].
Tildrakizumab reduces IL-23’s affinity for IL-23Rα through a negative allosteric modulation[2].
Tildrakizumab (100 mg/kg, s.c., every 2 weeks up to 9 months) is well tolerated in cynomolgus monkeys (toxicity studies)[3].
References:
[1]. Papp K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.
[2]. Zhou L, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021 Jan-Dec;13(1):1964420.
[3]. Santostefano M, et al. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates. Regul Toxicol Pharmacol. 2019 Nov;108:104476.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *